UHBMyeloid

State-of-the-Art diagnostics and management of myeloid malignancies in Birmingham.

[NEJM @NEJM]

In a phase 1 study of the oral p53 reactivator rezatapopt in heavily pretreated patients with TP53 Y220C–mutated solid tumors, the most common adverse events were nausea and vomiting, and the overall response was 20%. Full PYNNACLE study results: https://t.co/LBqROGlouc

Science behind the Study: Restoring Function to a Variant of p53 in Solid Tumors https://t.co/5Ox6Kuax6Q

[Dr Tony Goldstone @goldstone_tony]

ICYMI - Self assessment deadline is now just over 2 weeks away. If you are struggling with what to write regarding your annual allowance, see my video from the weekend below 👇

[Benlazar S M A @smbenlazar]

Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms https://t.co/Y7QhW5DfHd #AML #leusm @n_gangat

[Blood Advances @BloodAdvances]

DNMT3A, TET2, and ASXL1 mutations differentially shape the subsequent evolutionary trajectories of AML from diagnosis through relapse. https://t.co/MKxqP7Qhdg #myeloidneoplasia

[UHBMyeloid @UhbTeam]

Thanks @HaemOnc, @VidhyaMurthy1, Hayley @UHBResearch, @charliecraddock, @h4yder for another great West Mids Myeloid Day on relapsed refractory #AML,high risk#MDS, and #CML. And cases from Richard Whitmill and Matt Kandathil @RWT_NHS

[Lee Grimes Lab @LeeGrimesLab]

Why do AML patients with African ancestry have poor outcomes? Fascinating results indicate that genetics alter AML biology. Also, its Bailee Kain's first co-first author postdoc pub. @Bailee_Kain @AkEisfeld @nsalomonis and Elaine Mardis
https://t.co/jG0z4sWaNT

[Charlie Craddock CBE @charliecraddock]

Hugely important talk from @drpramilak on impact of ethnicity on patient outcome in AML. Emerging evidence of distinct disease biology and decreased transplant access contributing to worse outcomes. Vital area for research and action- supports launch of UK Myecare AML Registry.

[UHBMyeloid @UhbTeam]

@HaemOnc @LabMonteiro @Farhat_Khanim @neilvmorgan @HrushiVyas @REPAIR_MDS We are very saddened at the sudden passing of our colleague and friend @SandeepNagra who supported the transplant and haematology team for many years. She will be dearly missed by us and many patients who she helped. Our sincere condolences to her family at this time

[UHBMyeloid @UhbTeam]

Great regional myeloid meeting at Exchange @unibirmingham with @WMRGL @VidhyaMurthy1 giving changes in guidances for #aml treatment

[UHBMyeloid @UhbTeam]

@HaemOnc latest in low risk #MDS and inherited risks in #AML highlighting work by @LabMonteiro @Farhat_Khanim @neilvmorgan @HrushiVyas @REPAIR_MDS

[Pip Nicolson @PipNicolson]

Getting excited about seeing @HaemSTAR_UK #RAPIDO data at #BSH2024…2 hours to go

[Sridhar Chaganti @SridharChaganti]

Brilliant work by my colleague @lymphomule. Most MYC/BCL6r lymphomas harbour a single-hit, reciprocal translocation t(3;8) between MYC and BCL6 (pseudo double-hit) and have better outcomes than t(3;8) negative double-hit cases. https://t.co/7OeWViqjaT

[Vidhya Murthy @VidhyaMurthy1]

@UhbTeam @francescakinse3 @HaemOnc @h4yder @dr_peted @charliecraddock
Our second regional myeloid update day with focus on MPN. Great talks and fantastic case studies from colleagues.

[Marcel van den Brink @DrMvandenBrink]

A giant leaves us

https://t.co/3iC2lgQHTf

[Justin Loke @jloke1]

Thanks to @TheEBMT @Mohty_EBMT Myriam labopin and the ALWP team for this analysis and @charliecraddock for inspiration in clinic!- kinetics of CR induction matters to post allo sct prognosis.

[Beth Psaila @beth_psaila]

Delighted to share our @NatureProtocols paper containing a detailed protocol for generating human bone marrow organoids. Amazing teamwork from the organoid crew @MRC_WIMM @UniofOxford led by the unstoppable @AbAttacks 🎉👇👇👏🏻

[Blood Advances @BloodAdvances]

Blast-reduction strategies in MPN-AP/BP most commonly result in reversion to chronic phase MPN with significant residual disease burden. https://t.co/ztIOeOulGE #myeloidneoplasia

[Benlazar S M A @smbenlazar]

Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee https://t.co/qrhaXU4dkb #CMML #leusm

[RC of Pathologists @RCPath]

'We passionately believe that critical appraisal of trials is a core skill that all healthcare professionals should be able to perform.'

We interview Drs Rich Buka and Pip Nicholson on their new podcast series discussing non-malignant haematology.

https://t.co/Z3LDpCdDvd